Open Access

PAX2 promotes epithelial ovarian cancer progression involving fatty acid metabolic reprogramming

  • Authors:
    • Yan Feng
    • Yong Tang
    • Yannan Mao
    • Yingzhao Liu
    • Desheng Yao
    • Linkai Yang
    • Kenneth Garson
    • Barbara C. Vanderhyden
    • Qi Wang
  • View Affiliations

  • Published online on: January 10, 2020     https://doi.org/10.3892/ijo.2020.4958
  • Pages: 697-708
  • Copyright: © Feng et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Ovarian cancer is the fifth most common type of cancer afflicting women and frequently presents at a late stage with a poor prognosis. While paired box 2 (PAX2) expression is frequently lost in high‑grade serous ovarian cancer, it is expressed in a subset of ovarian tumors and may play a role in tumorigenesis. This study investigated the expression of PAX2 in ovarian cancer. The expression of PAX2 in a murine allograft model of ovarian cancer, the RM model, led to a more rapidly growing cell line both in vitro and in vivo. This finding was in accordance with the shorter progression‑free survival observed in patients with a higher PAX2 expression, as determined in this study cohort by immunohistochemistry. iTRAQ‑based proteomic profiling revealed that proteins involved in fatty acid metabolism and oxidative phosphorylation were found to be upregulated in RM tumors expressing PAX2. The expression of two key fatty acid metabolic genes was also found to be upregulated in PAX2‑expressing human ovarian cancer samples. The analysis of existing datasets also indicated that a high expression of key enzymes in fatty acid metabolism was associated with a shorter progression‑free survival time in patients with serous ovarian cancer. Thus, on the whole, the findings of this study indicate that PAX2 may promote ovarian cancer progression, involving fatty acid metabolic reprograming.
View Figures
View References

Related Articles

Journal Cover

March 2020
Volume 56 Issue 3

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
APA
Feng, Y., Tang, Y., Mao, Y., Liu, Y., Yao, D., Yang, L. ... Wang, Q. (2020). PAX2 promotes epithelial ovarian cancer progression involving fatty acid metabolic reprogramming. International Journal of Oncology, 56, 697-708. https://doi.org/10.3892/ijo.2020.4958
MLA
Feng, Y., Tang, Y., Mao, Y., Liu, Y., Yao, D., Yang, L., Garson, K., Vanderhyden, B. C., Wang, Q."PAX2 promotes epithelial ovarian cancer progression involving fatty acid metabolic reprogramming". International Journal of Oncology 56.3 (2020): 697-708.
Chicago
Feng, Y., Tang, Y., Mao, Y., Liu, Y., Yao, D., Yang, L., Garson, K., Vanderhyden, B. C., Wang, Q."PAX2 promotes epithelial ovarian cancer progression involving fatty acid metabolic reprogramming". International Journal of Oncology 56, no. 3 (2020): 697-708. https://doi.org/10.3892/ijo.2020.4958